Non-invasive tests of non-alcoholic fatty liver disease

作     者：Guanlin Li Xinrong Zhang Huapeng Lin Lilian Yan Liang Grace Lai-Hung Wong Vincent Wai-Sun Wong Guanlin Li;Xinrong Zhang;Huapeng Lin;Lilian Yan Liang;Grace Lai-Hung Wong;Vincent Wai-Sun Wong

作者机构：Department of Medicine and TherapeuticsThe Chinese University of Hong KongHong KongChina State Key Laboratory of Digestive DiseaseThe Chinese University of Hong KongHong KongChina Medical Data Analytics CentreThe Chinese University of Hong KongHong KongChina 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2022年第135卷第5期

页      面：532-546页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：The Chinese University of Hong Kong (project reference 2020.045)。 

主　　题：Fatty liver Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Liver fibrosis Cirrhosis Transient elastography FibroScan Magnetic resonance imaging 

摘      要：For the detection of steatosis,quantitative ultrasound imaging techniques have achieved great progress in past years.Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis.Some blood biomarkers correlate with non-alcoholic steatohepatitis,but the accuracy is modest.Regarding liver fibrosis,liver stiffness measurement by transient elastography(TE)has high accuracy and is widely used across the world.Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability.Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response.This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease(NAFLD).Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD,assess its severity,and predict the prognosis.Further studies are needed to determine the role of the tests as monitoring tools.We cannot overemphasize the importance of context in selecting appropriate tests.